Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

Tomas Olsson, Anat Achiron, Lars Alfredsson, Thomas Berger, David Brassat, Andrew Chan, Giancarlo Comi, Mefkure Eraksoy, Harald Hegen, Jan Hillert, Poul Erik Hyldgaard Jensen, Lucia Moiola, Kjell Morten Myhr, Annette Oturai, Sven Schippling, Aksel Siva, Per Soelberg Sorensen, Anne Kathrin Trampe, Thomas Weber, James PottsTatiana Plavina, Dominic Paes, Meena Subramanyam, Heinz Wiendl, Hussein Dib, Deniz Üren, Bernhard Hemmer, Dorothea Buck

Research output: Contribution to journalArticlepeer-review

88 Scopus citations


JC virus (JCV) is an opportunistic virus known to cause progressive multifocal leukoencephalopathy. Anti-JC virus (Anti-JCV) antibody prevalence in a large, geographically diverse, multi-national multiple sclerosis (MS) cohort was compared in a cross-sectional study. Overall, anti-JCV antibody prevalence was 57.6%. Anti-JCV antibody prevalence in MS patients ranged from approximately 47% to 68% across these countries: Norway, 47.4%; Denmark, 52.6%; Israel, 56.6%; France, 57.6%; Italy, 58.3%; Sweden, 59.0%; Germany, 59.1%; Austria, 66.7% and Turkey, 67.7%. Prevalence increased with age (from 49.5% in patients < 30 years of age to 66.5% in patients ≥ 60 years of age; p < 0.0001 comparing all age categories), was lower in females than in males (55.8% versus 61.9%; p < 0.0001) and was not affected by prior immunosuppressant or natalizumab use.

Original languageEnglish
Pages (from-to)1533-1538
Number of pages6
JournalMultiple Sclerosis Journal
Issue number11
StatePublished - Oct 2013
Externally publishedYes


  • JC virus
  • Multiple sclerosis
  • anti-JCV antibodies
  • antibody prevalence
  • brain infection
  • epidemiology
  • immunosuppressant therapy
  • infection risk
  • international study
  • natalizumab


Dive into the research topics of 'Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort'. Together they form a unique fingerprint.

Cite this